Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACE relacorilant randomized-withdrawal study in endogenous Cushing syndrome
2018-003096-35Phase 3Completed
- Sponsor
- Corcept Therapeutics
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in endogenous Cushing's syndrome comparing Relacorilant with Placebo (2 arms). Primary endpoint: Blood pressure control at Week 12 of the randomized-withdrawal phase. Started Dec 2018; status: completed.
02
Drugs
relacorilant
03
Conditions
endogenous Cushing's syndrome
Beyond the preview
Go deeper on 2018-003096-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003096-35.